Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day

Virtual R&D Day featuring key opinion leaders and Poseida’s scientific team members to be held today, at 10:00am ET /7:00am PT

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today, February 24, 2021 beginning at 10am ET.